What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Cancer
Rafael Simó spends much of his time researching Internal medicine, Diabetes mellitus, Diabetic retinopathy, Endocrinology and Retina.
His Internal medicine study incorporates themes from Type 2 Diabetes Mellitus and Hepatitis C virus.
Rafael Simó interconnects Vitrectomy, Surgery and Immunology in the investigation of issues within Diabetes mellitus.
His Diabetic retinopathy study combines topics in areas such as Pathogenesis, Ophthalmology, Adverse effect, Vascular endothelial growth factor and Disease.
His work in the fields of Endocrinology, such as Insulin resistance and Liraglutide, overlaps with other areas such as Downregulation and upregulation.
His work carried out in the field of Retina brings together such families of science as Retinal and Neurodegeneration.
His most cited work include:
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial (716 citations)
- The progress in understanding and treatment of diabetic retinopathy (315 citations)
- Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. (299 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Endocrinology, Diabetes mellitus, Diabetic retinopathy and Type 2 diabetes.
Rafael Simó has researched Internal medicine in several fields, including Gastroenterology, Type 1 diabetes and Cardiology.
His biological study spans a wide range of topics, including Retinal pigment epithelium and Vitrectomy.
His Diabetes mellitus research is multidisciplinary, incorporating perspectives in Vascular endothelial growth factor, Surgery, Immunology and Pulmonary function testing.
His Diabetic retinopathy research incorporates elements of Ophthalmology, Retinal, Neurodegeneration, Disease and Retina.
His research in Type 2 diabetes intersects with topics in Metformin, Dementia and Type 2 Diabetes Mellitus.
He most often published in these fields:
- Internal medicine (74.19%)
- Endocrinology (46.02%)
- Diabetes mellitus (44.52%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (74.19%)
- Diabetes mellitus (44.52%)
- Type 2 diabetes (28.60%)
In recent papers he was focusing on the following fields of study:
Rafael Simó mainly investigates Internal medicine, Diabetes mellitus, Type 2 diabetes, Diabetic retinopathy and Dementia.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Endocrinology.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Referral, Disease, Confidence interval and Intensive care medicine.
His Type 2 diabetes research is multidisciplinary, relying on both Oxygen homeostasis, Weight loss, Cardiology, Cognition and Type 2 Diabetes Mellitus.
The study incorporates disciplines such as Retinopathy, Retinal, Pharmacology and Cognitive impairment in addition to Diabetic retinopathy.
His Dementia research incorporates elements of Ophthalmology, Meta-analysis, Framingham Risk Score and Pediatrics.
Between 2018 and 2021, his most popular works were:
- Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. (40 citations)
- Screening for diabetic retinopathy: new perspectives and challenges (31 citations)
- Screening for diabetic retinopathy: new perspectives and challenges (31 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Diabetes mellitus
Rafael Simó focuses on Diabetic retinopathy, Internal medicine, Diabetes mellitus, Type 2 diabetes and Retinal.
Rafael Simó combines subjects such as Cytokine, Pharmacology, Pathogenesis and Cognitive impairment with his study of Diabetic retinopathy.
His research investigates the connection with Internal medicine and areas like Endocrinology which intersect with concerns in Mitochondrial biogenesis.
The concepts of his Diabetes mellitus study are interwoven with issues in Randomized controlled trial and Somatostatin.
The study incorporates disciplines such as Placebo, Intensive care medicine, Disease and Cardiology in addition to Type 2 diabetes.
His study in Retinal is interdisciplinary in nature, drawing from both Proinflammatory cytokine, Neuroinflammation and Db/db Mouse.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
